Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-α/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):286-90. doi: 10.1097/QAI.0000000000000608.

Abstract

We analyzed the effect of interferon α (IFN-α) and ribavirin (RBV) therapy on cell-associated human T-lymphotropic virus type 2 (HTLV-2) DNA in HIV-1-coinfected patients receiving antiretroviral therapy. Sixty-one patients under suppressive antiretroviral therapy were included: 37 with hepatitis C virus (HCV) infection, 15 with sustained virologic response (N = 10), relapse (N = 2), or with nonresponse (N = 3) after IFN-α/RBV treatment, and 9 with spontaneous HCV RNA clearance. Patients who were treated with IFN-α/RBV or had spontaneous HCV clearance had lower level of cell-associated HTLV-2 DNA (P = 0.022 and P = 0.040, respectively). Both IFN-alpha treatment and the ability to spontaneously clear HCV infection seem to reduce cell-associated HTLV-2 DNA in HIV-1-coinfected patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • CD8-Positive T-Lymphocytes / immunology
  • DNA, Viral / isolation & purification*
  • Female
  • HIV Infections / complications*
  • HIV Infections / virology
  • HIV-1
  • Hepacivirus / classification
  • Hepacivirus / genetics
  • Hepatitis C / complications*
  • Hepatitis C / virology
  • Human T-lymphotropic virus 2 / genetics*
  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use
  • Interleukin-6 / metabolism
  • Male
  • Middle Aged
  • RNA, Viral / immunology*
  • Ribavirin / administration & dosage
  • Ribavirin / therapeutic use

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • DNA, Viral
  • Interferon-alpha
  • Interleukin-6
  • RNA, Viral
  • Ribavirin